DBS effectiveness in treating addiction remains uncertain amid inconsistent results

Deep brain stimulation helps manage movement in patients with neurological disorders

DBS is a surgical procedure that uses implanted electrodes to send electrical signals to targeted areas in the brain, interrupting abnormal neural activity. It may be implemented when medications lose effectiveness or cause disruptive side effects.

Neural interfaces offer major medical potential but raise serious ethical concerns

Although brain-computer interfaces can help people recover lost functions and allow direct brain-to-computer communication in the future, surveys have shown little public support for using them to boost abilities like memory or focus in healthy people.

Chronic drug use can cause neurological changes in the brain

Neuroscientist Judy Grisel breaks down the biology of addiction, examining how drugs hijack the brain’s natural reward system and create lasting neural changes. The physiological and neurological impacts of chronic drug use require a multifaceted treatment approach.

Drug tolerance and withdrawals are consequences of overloading dopamine circuits

Addictive substances or behaviors will typically flood our brains with more dopamine than usual. In response to the overstimulation, our brains will decrease the number of available dopamine receptors. This results in the need for more stimulus for the same response (tolerance) and a rise in negative feelings when the stimulus is absent (withdrawal).

The science of addiction treatment

A helpful resource from the National Institute on Drug Abuse (part of the NIH). This article examines addiction treatment and recovery through the science behind several accepted methods. The guide draws helpful comparisons with other chronic disease treatments. In particular, it discusses the overlap between medications and therapeutic treatments, and the understanding that relapse doesn’t indicate treatment failure—only a need for continued or modified care.

Addictive drugs can cause dopamine levels to become ten times higher than normal.

Predictive brain implants raise ethical concerns about patient autonomy after surgery

These devices can accurately forecast neurological events like seizures and suggest or even automatically deliver responses. Their constant monitoring and prescriptive functions may blur the line between patient choice and device influence.

Open brain surgery is not required for BCIs inserted via blood vessel injection

Synchron's brain-computer interface, the Synchron Switch, takes advantage of preexisting medical devices, such as stents and catheters. Cells grow over the device over a 90-day period, incorporating it into the vessel wall and minimizing clots.

Addiction is defined as chronic compulsive drug use despite adverse consequences

This resource from the National Institute on Drug Abuse provides a comprehensive look at addiction as a complex brain disorder. It explores why people initially take addictive substances and how continued use alters the brain’s reward system.

Addiction develops when the pleasure circuits in the brain get overwhelmed

Normal pleasure circuits become overwhelmed by addictive substances, triggering dopamine floods many times stronger than those induced by everyday reward experiences. The understanding of addiction as a brain disease has led to treatments pairing medication and counseling.

Ibogaine is being investigated for treating mental health issues and substance abuse

This compound, which is illegal to use in the US, has had promising results for patients who have tried it in other countries for substance abuse and mental health concerns. This psychoactive substance is not without risks, however; this TED talk points out it's also caused fatal cardiac arrhythmias and shouldn't be taken without medical supervision.

Veterans reported single dose of ibogaine improved TBI, PTSD, anxiety, and depression

Research published in 2024 on the Central African plant-derived drug included 30 male combat vets who received ibogaine treatment in Mexico. It reported significant reductions in multiple mental health conditions and no serious side effects. Other work, however, has shown the substance can cause fatal cardiac arrhythmias, killing at least 19 people between 1990 and 2008. (Some users may encounter a paywall.)

Depression changes the brain, causing distinct structural alterations visible on brain scans, but effective treatment can eventually make a depressed brain resemble a healthy one.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010, but two anti-amyloid infusion medications have netted FDA approval in recent years.

Implanted neurotechnology can leave users vulnerable when manufacturers go under

Despite providing relief from neurological conditions, patients are left stranded when the companies that make these devices shut down. The lack of regulation means patients often face technical failure, insurance battles, or risky surgeries to maintain their quality of life.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

Losing a brain-computer interface can trigger lasting psychological distress

A clinical trial participant with severe epilepsy described becoming “one” with her implant after it gave her unprecedented control over her seizures. When the device was removed due to the company shutting down, she experienced deep emotional trauma and a sense of personal loss.

Interface device implanted into ALS patients restored some of their abilities

Most people with amyotrophic lateral sclerosis, or Lou Gehrig's disease, require assistance with daily life due to loss of motor control. The electrode-coated, stent-like device used motor mapping data and machine learning to translate brain activity into actions.

Why the human brain loves opioids

When opioids enter the brain, they dock in receptors, blocking electrical pulses such as those that communicate pain. They also trigger the release of dopamine, a neurotransmitter tied to motivation and associated with stress relief.

Brain implants are restoring movement and communication in early human trials

Several companies developing brain-computer interfaces have begun testing on humans with promising results. These implants have helped reanimate paralyzed limbs and enable communication, though ethical concerns remain about data privacy.

Psychedelic side effects, including worsening mental health for some patients, give pause

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

Mixed reality technologies may help treat depression

A study led by a team from Stanford University showed that MR can help people with depression by providing pathways to engage in activities such as digital board games and dancing. Participants saw reduced symptoms of depression that made their overall treatment plans more successful.

A 49-year-old American died at an ibogaine clinic in Mexico, underscoring its risks

The man had sought out the drug to help him overcome his substance abuse disorder. Though anecdotal reports indicate potential promise, there's been no large-scale clinical trials on ibogaine's safety and efficacy. The plant is derived from a root bark named iboga and has been used for centuries by indigenous communities in Gabon, but first entered scientific consciousness in 1901 after its alkaloid was isolated from Iboga.

Ibogaine, a psychedelic substance, can be used to treat mental illness

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.

'Susan's Brain': what happens to the brain during addiction

This engaging animation from Harvard Online breaks down the neuroscience of addiction through the story of “Susan’s brain,” demonstrating how addictive substances hijack normal reward pathways. Through clear visual metaphors and approachable narration, it explains complex brain chemistry in understandable terms.

Psychedelic DMT—part of ayahuasca—shows antidepressant promise in small clinical trial

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

Social media addiction, though not a clinical diagnosis, refers to the idea that infinite scroll, notifications, and algorithms override one's ability to stop using them.

Can the gut microbiome drive addiction?

New research suggests an imbalance of gut microorganisms may influence the likelihood of addiction and addictive behaviors by increasing the severity of withdrawal symptoms, triggering brain inflammation in regions of impulse control, and more.

An essay exploring how living day-to-day with a brain implant helps restore a sense of identity

Companies like Neuralink are experimenting with volunteers who have lost control over their bodies. Many of the program's participants claim the most significant benefit from the tool is the ability to perform simple, mundane tasks, such as playing video games or shaking hands, rather than more obvious milestones like walking or eating. This essay explores what it's like, day to day, to use a brain implant.

Antidepressants alone may fail to help an estimated one-third to one-half of depressed patients.

Oregon voters in 2020 greenlit adult use of psilocybin—the active ingredient in magic mushrooms—in state-licensed centers, and a 2026 analysis indicates the program has good safety and satisfaction data.

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

Some experts equate prediction markets to the new crack cocaine of gambling addiction

An addiction psychiatrist at UCLA says betting apps are far more potent than traditional gambling, citing a 19-year-old patient who lost $180,000 and hadn't left campus in a year, cycling through sports bets, crypto, meme stocks, and prediction markets on his phone. This interview explores the extreme edge of the nascent industry.

Australian psychiatrists already prescribe psilocybin and MDMA for depression and PTSD

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

How psilocybin could transform mental health treatment

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

Bupropion is the only antidepressant approved for the preventive treatment of SAD

Clinical trials showed a 44% reduction in risk for recurrence of SAD for those who took the drug compared to a placebo group. Bupropion is a norepinephrine–dopamine reuptake inhibitor, which increases dopamine (other common antidepressants, known as selective serotonin reuptake inhibitors, sometimes can suppress dopamine, but not always).

Stem cell therapy has shown promise in treating spinal injuries in an early-stage clinical trial.

Psychedelics interact with neurotransmitter systems to alter one's perception

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

A new schizophrenia healthcare model is giving patients more of a role in shaping their own treatments, with good results.

Methadone binds to the same receptors as heroin and other opioids

Methadone is a long-acting opioid agonist that works by binding to the same brain receptors as other opioids (like heroin or morphine), but without producing intense euphoria. It reduces withdrawal symptoms and cravings, helping people stabilize and avoid illicit opioid use.

Support groups can offer insights into current and potential treatments

Beyond connecting with patients with similar experiences, support groups can also become centers for advocacy and for sharing research advances and medical experiences, including potential side effects from novel therapies or clinical trials.

Mental health applications of psychedelics

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

Fantasy sports can have adverse health effects

Experts warn that fantasy sports, including fantasy football, can encourage obsessive use because they offer hits of dopamine. Daily fantasy games, which function more like gambling, are especially problematic.

Schizophrenia is being studied with pea-sized 'mini-brains'

Brain organoid research is enabling researchers to study distinct electrical firing patterns associated with schizophrenia. These "mini-brains" that are constructed in the lab from patients' cells could lead to better diagnosis approaches and drug development.

Social support plays a critical role in recovery from addiction

This engaging TEDx talk from addiction researcher Jacki Hillios explores addiction recovery through a transformative lens and Phoenix Multisport—an innovative program helping people rebuild their lives through active lifestyles. By living out its core message that people are not defined by their disease, the program demonstrates the power of social support in recovery.

Using AI to restore speech 30 years after a stroke

Through a novel surgical procedure involving electrodes implanted in the brain, along with the help of artificial intelligence, a stroke patient is regaining her ability to speak. This technology converts her thoughts into speech through a digital avatar, allowing her to verbally express herself for the first time in decades.

Naltrexone blocks the reward effects of alcohol and opioids

Naltrexone is used to treat alcohol and opioid dependence, blocking opioid receptors in the brain, reducing cravings, and preventing the euphoric effects of alcohol or opioids. It is nonaddictive and works best as part of a comprehensive treatment plan, including counseling or therapy, to support long-term recovery.

Neural implants blur the line between personal intention and machine execution

A key ethical dilemma—the contemplation conundrum—explores whether implants might misinterpret mere imagination as intent to act. Neuroscientists have found no brain signal that clearly marks when someone decides to act, making intent hard to detect in neurotechnological systems.

The body produces its own opioids that act on several receptor types throughout the body, triggering the release of dopamine and suppression of noradrenaline, neurotransmitters associated with reward and alertness, respectively.